Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

User asks if mixing RU58841 solution with Serioxyl is okay for better scalp coverage and worries about reduced effects.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

The user switched from finasteride to DIY dutasteride mesotherapy and topical minoxidil due to side effects. They report improved well-being and no hair loss worsening after stopping finasteride.

RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.

A user is seeking advice on making a topical bicalutamide solution as an alternative to RU58841 for hair loss, while already using dutasteride and minoxidil. They are considering crushing bicalutamide pills and adding them to their minoxidil.

A 22-year-old is frustrated with ongoing hair loss despite using treatments like topical minoxidil, finasteride, microneedling, oral dutasteride, and oral minoxidil. Their dermatologist suggests treating scalp inflammation with oral tretinoin and using exosomes for alopecia.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation discusses using a custom topical from Skin Medicinals containing latanoprost for hair loss, which helps move hairs into the anagen phase. The user is curious about the cost and effectiveness of this treatment.

The conversation discusses using propanediol as an alternative to glycerin in PG-free minoxidil for better absorption. The user also plans to try nanoxidil, which may absorb more easily due to its smaller molecule size.

The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.

The user is using a hair loss treatment regimen that includes RU58841, minoxidil mixed with finasteride, adenosine, dermarolling with lidocaine cream, and biotin. They are questioning if they are dermarolling too aggressively and are willing to accept baldness if no improvement is seen in 6 months.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

Topical spironolactone is available in the UK for men to block androgen receptors locally. The user seeks opinions or experiences from others who have used it.

RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

Bimatoprost is discussed for hair and eyelash growth, with users confirming its legitimacy and availability from Indian pharmacies. It is noted that the common concentration may not be effective for significant scalp hair regrowth unless mixed with Minoxidil.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Combining topical finasteride with RU58841 for hair loss treatment. Users discuss the effectiveness and potential side effects of oral and topical finasteride.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.